#prospect-coverage

#prospect-coverage

Chinese stocks have spent the last five years really testing the patience of even the most hardcore contrarians. Between the property sector struggles, the crackdown on tech platforms, and the constant friction over chip exports and tariffs, valuations have been pushed down across the board.

The iShares Biotechnology ETF is the default large-cap vehicle for the sector. It is market-cap weighted, which concentrates the fund in cash-generative incumbents rather than spreading capital across clinical-stage names.

Some financial experts recommend enjoying a portion of the windfall while allocating the rest towards savings or investments to ensure long-term benefits.

We see people asking all these questions to ChatGPT and Claude, but those services are not optimized. Astor is built on a multi-agent architecture that draws on Anthropic models.

For most companies, there's roughly a 12-month period where the business is at its peak value, and then it crashes out. The companies that capture generational returns are often the ones where someone spies that moment instead of assuming the good times will get even better.

Cursor is nearing a funding round of at least $2 billion, with returning investors Thrive and Andreessen Horowitz expected to lead the financing at a $50 billion valuation. The deal terms are not final and may still change.

Awards may be encouraging and occasionally useful for visibility, but they are weak indicators of validation and poor predictors of long-term success. In the longevity and healthspan industry, where timelines are long and claims are easy to overstate, venture capital ultimately follows alignment and evidence, not applause received at glitzy industry events.